

**Jubilant Life Sciences Ltd**  
**Unaudited Financial Results for the Quarter and Nine Months ended 31st December, 2011**

( ₹ in Lacs)

Particulars	CONSOLIDATED RESULTS					
	Quarter Ended			Nine Months Ended		Year Ended
	December 31	September 30	December 31	December 31		March 31
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
	2011	2011	2010	2011	2010	2011
<b>Net sales/Income from operations</b>	<b>108717</b>	<b>104808</b>	<b>86647</b>	<b>307954</b>	<b>254306</b>	<b>343340</b>
Other Operating Income	132	200	250	751	480	883
<b>Total income</b>	<b>108849</b>	<b>105008</b>	<b>86897</b>	<b>308705</b>	<b>254786</b>	<b>344223</b>
<b>Total expenditure</b>	<b>93399</b>	<b>86282</b>	<b>78610</b>	<b>260885</b>	<b>227294</b>	<b>306812</b>
a) (Increase)/Decrease in stock in trade and work in progress	(10461)	(4522)	1073	(19184)	(832)	(3880)
b) Purchase of traded goods	8345	6554	7289	21484	17603	24007
c) Raw & process materials consumed	41140	36657	26805	111375	82368	112943
d) Stores, spares, chemicals, catalyst & packing material consumed	6314	5113	5679	17299	16112	21188
e) Power & fuel	7749	5822	5523	19572	16044	22404
f) Other manufacturing expenses	2568	2539	1473	6910	4762	6965
g) Staff cost	22817	20603	17765	62396	53543	71842
h) Depreciation	5389	5080	4928	15446	14696	18010
i) Other Expenditure (Selling, general & admin. Expenses-Including Exchange Loss/Gain)	9538	8436	8075	25587	22998	33333
<b>Operating profit before Other Income &amp; Interest</b>	<b>15450</b>	<b>18726</b>	<b>8287</b>	<b>47820</b>	<b>27492</b>	<b>37411</b>
Other Income	351	340	168	1058	825	1296
<b>Profit before Interest &amp; Exceptional Items</b>	<b>15801</b>	<b>19066</b>	<b>8455</b>	<b>48878</b>	<b>28317</b>	<b>38707</b>
Interest (Net)	5662	4969	2856	14969	7279	10506
<b>Profit after Interest but before Exceptional Items</b>	<b>10139</b>	<b>14097</b>	<b>5599</b>	<b>33909</b>	<b>21038</b>	<b>28201</b>

Particulars	CONSOLIDATED RESULTS					
	Quarter Ended			Nine Months Ended		Year Ended
	December 31	September 30	December 31	December 31		March 31
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		(Audited)
	2011	2011	2010	2011	2010	2011
Exceptional items	15549	4260	230	20227	2601	4142
<b>Profit from Ordinary Activities before Tax</b>	<b>(5410)</b>	<b>9837</b>	<b>5369</b>	<b>13682</b>	<b>18437</b>	<b>24059</b>
Tax Expenses (Net)	888	930	1037	3334	1875	1336
<b>Net profit from Ordinary Activities after Tax</b>	<b>(6298)</b>	<b>8907</b>	<b>4332</b>	<b>10348</b>	<b>16562</b>	<b>22723</b>
Extraordinary Items (net of tax expenses)	-	-	-	-	-	-
Minority Interest	1541	971	(79)	2539	(238)	(249)
<b>Net profit after Minority Interest</b>	<b>(7839)</b>	<b>7936</b>	<b>4411</b>	<b>7809</b>	<b>16800</b>	<b>22972</b>
Paid-up share capital (Face value per share ₹ 1 )	1593	1593	1593	1593	1593	1593
Reserves (excluding revaluation reserve)						215634
Earnings per share before and after extraordinary items (Not annualized)						
<b>Basic (₹)</b>	<b>(4.92)</b>	<b>4.98</b>	<b>2.77</b>	<b>4.90</b>	<b>10.55</b>	<b>14.42</b>
<b>Diluted (₹)</b>	<b>(4.92)</b>	<b>4.98</b>	<b>2.50</b>	<b>4.90</b>	<b>9.54</b>	<b>13.04</b>
<b>Public shareholding</b>						
- Number of shares ( ₹ 1 each)	81166083	81344677	84129115	81166083	84129115	84129115
- Percentage of shareholding	50.96	51.07	52.82	50.96	52.82	52.82
<b>Promoters and promoter group Shareholding</b>						
<b>a) Pledged/Encumbered</b>						
- Number of shares	4257000	6552333	7228300	4257000	7228300	7531333
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	5.45	8.41	9.62	5.45	9.62	10.02
- Percentage of shares (as a % of the total share capital of the company)	2.67	4.11	4.54	2.67	4.54	4.73
<b>b) Non-Encumbered</b>						
- Number of shares	73858056	71384129	67923724	73858056	67923724	67620691
- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	94.55	91.59	90.38	94.55	90.38	89.98
- Percentage of shares (as a % of the total share capital of the company)	46.37	44.82	42.64	46.37	42.64	42.45

**Notes:**

1. The Company's operates under one reportable segment viz. Pharmaceuticals and Life Sciences Products and Services (PLSPS).
2. The Company has opted for accounting of exchange difference arising on reporting of long term monetary items under Clause 46 A of AS 11 on "The Effects of Changes in Foreign Exchange Rates" as per notification No GSR 914(E) issued by the Ministry of Corporate Affairs Government of India on 29th December ,2011. Accordingly exchange differences amounting to ₹ 4108 Lacs has been amortized during the nine months period ending 31st December, 2011 and balance ₹ 10949 Lacs has been carried forward under Foreign Currency Monetary Items Translation Difference Account (FCMITDA) to be amortized over the balance life of the respective loan and ₹ 641 Lacs has been taken to Capital work in Progress.
3. The company has opted for hedge accounting in respect of certain transactions including forward contracts under Accounting Standard 30 issued by the Institute of Chartered accountants of India during the period and the debit balance in hedge reserve as at 31st December 2011 is ₹ 6582 Lacs (Consolidated ₹ 7259 Lacs) .
4. During the quarter the company acquired 100% stake in an entity which holds 4.20% shares in its subsidiary Jubilant First Trust Healthcare Limited (JFTH) and as a result JFTH has become wholly owned Subsidiary of the Company .
5. During the quarter the Company has commenced commercial production of Nutrition Ingredients and Fine Chemicals at its SEZ in Bharuch, Gujarat .
6. Exceptional items include :
  - i) Amortization of Foreign Currency Monetary Item Translation Difference Account-loss/(gain) ₹ 1257 Lacs (Consolidated ₹ 1257 Lacs) for Q3-FY 2012 and ₹ 4108 Lacs (Consolidated ₹ 4108 Lacs) for 9M-FY 2012.
  - ii) Mark to Market in respect of Currency & Interest rate swap contracts and Forward Covers outstanding at the period end resulting in loss/(gain) amounting to ₹ 14065 Lacs (Consolidated ₹ 14292 Lacs) for Q3-FY 2012 and ₹ 15642 Lacs (Consolidated ₹ 16119 Lacs) for 9M-FY 2012.
7. Tax Expenses are net after considering the Deferred Tax charge/credit and MAT Credit Entitlement .
8. Information on investors complaints for the quarter (Nos.): Opening Balance - Nil, New -32 , Disposals -32, Closing Balance - Nil.
9. Previous year / periods figures have been regrouped/reclassified wherever necessary.
10. The above un-audited results were , subjected to limited review by the auditors of the Company, reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 6th February, 2012.

Place : Noida

For Jubilant Life Sciences Ltd.

Dated : 6th February, 2012

Shyam S Bhartia  
Chairman & Managing Director